Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature

Santiago Graua Pharmacy Department, Hospital Del Mar, Barcelona, SpainView further author information

Jose Maria Mirób Department of Infectious Diseases, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain;c CIBERINFEC, Instituto de Salud Carlos III, Madrid, SpainView further author information

Julian Olallad Internal Medicine Department, Hospital Costa Del Sol, Marbella, SpainView further author information

Juan C Alcaláe Gilead Sciences, Madrid, SpainView further author information

Antonio Castroe Gilead Sciences, Madrid, SpainView further author information

Dario Rubio-Rodríguezf Health Value, Madrid, SpainView further author information

Carlos Rubio-Terrésf Health Value, Madrid, SpainCorrespondence[email protected]
View further author information

show all

Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date